Fig. 2
Effects of osimertinib and cisplatin combination in PC9T790M xenograft model. a PC9T790M cells were subcutaneously inoculated into BALB/C nude female mice, and after tumors had reached an average size of approximately 150mm3 the animals were treated with vehicle alone (ctrl), osimertinib (3 mg/kg once per day, five times per week) alone (osi), or osimertinib in combination with cisplatin (4 mg/kg once a day, twice per week) intercalated every week with osimertinib alone (osi + cis → osi). Tumor volume was measured twice per week and data are expressed as volume ± SEM (n = 8 tumors per group). *p < 0.05, **p < 0.01, vs osimertinib; two-way repeated measures analysis of variance followed by Bonferroni’s post-test. b Body weight was measured twice per week and data are expressed as percent change in body weight ± SEM (n = 8 tumors per group). *p < 0.05, **p < 0.01, ****p < 0.0001 vs osimertinib; two-way repeated measures analysis of variance followed by Bonferroni’s post-test. c The combined treatment was stopped on day 77, thereafter the tumor growth was monitored for further 35 days in four animals